<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640207</url>
  </required_header>
  <id_info>
    <org_study_id>ALM-Hyb-Pro-20-011</org_study_id>
    <nct_id>NCT04640207</nct_id>
  </id_info>
  <brief_title>The Efficacy of the Alma Hybrid System for a New Approach of Facial Skin Treatment</brief_title>
  <official_title>Prospective, Single-Center, Open-Label Study to Evaluate the Efficacy of the Alma Hybrid System for New Approach of Facial Skin Treatment With Minimal Downtime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alma Lasers</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alma Lasers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate the efficacy of the Alma Hybrid system for a new approach of&#xD;
      facial skin treatment, using both ablative and non-ablative wavelengths.&#xD;
&#xD;
      The study will include 20 subjects with mild-moderate photodamaged skin, that will undergo 2&#xD;
      facial skin treatments. Follow up visit to evaluate the efficacy of the treatments will take&#xD;
      place 1 and 3 months after the last treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Actual">July 18, 2021</completion_date>
  <primary_completion_date type="Actual">July 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator assessment</measure>
    <time_frame>3 month after last treatment</time_frame>
    <description>Investigator assessment of the overall facial skin aesthetic appearance using a 5 point Likert scale (when &quot;1&quot; indicate &quot;not at all improved&quot; and &quot;5&quot; indicates &quot; very much improved&quot;</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Rejuvenation</condition>
  <arm_group>
    <arm_group_label>Facial skin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facial skin treatment using the Alma Hybrid system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Facial skin treatment</intervention_name>
    <description>Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths</description>
    <arm_group_label>Facial skin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female, 35 to 60 years of age, at the time of enrollment&#xD;
&#xD;
          2. Fitzpatrick skin type I-IV&#xD;
&#xD;
          3. Mild-moderate photo damages and wrinkles, with Fitzpatrick-Goldman Wrinkle and&#xD;
             Elastosis Score of 3-6&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, intending to become pregnant during the course of study, less than 3 months&#xD;
             postpartum or less than 6 weeks after completion of breastfeeding&#xD;
&#xD;
          2. Heavy smoker (&gt;1 pack of cigarettes a day)&#xD;
&#xD;
          3. Unable or unlikely to refrain from tanning, including the use of tanning booths,&#xD;
             during the course of the study&#xD;
&#xD;
          4. Previous rejuvenation treatments on the same area, such as chemical peel,&#xD;
             dermabrasion, non-ablative or ablative resurfacing procedure, or face-lift with laser&#xD;
             or other devices, up to 3 months prior to the enrollment&#xD;
&#xD;
          5. Prior use of collagen, fat injections, or other methods of skin augmentation within&#xD;
             the past 12 months.&#xD;
&#xD;
          6. Prior use of Botox in the treatment area within 5 months&#xD;
&#xD;
          7. Infection, dermatitis, rash, or other skin abnormality in the target area&#xD;
&#xD;
          8. History of any disease or condition that could impair wound healing&#xD;
&#xD;
          9. History of keloid formation, hypertrophic scarring, or abnormal/delayed wound healing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Griffin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Associates of Plymouth Meeting, P.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Associates of Plymouth Meeting, P.C.</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

